Bempedoic Acid
Bempedoic acid
Bempedoic acid is the first non-statin oral lipid drug to demonstrate cardiovascular event reduction since ezetimibe. It lowers ApoB about 15-19% by inhibiting ATP-citrate lyase upstream of HMG-CoA reductase, without entering skeletal muscle - eliminating statin-like myopathy risk.
ATP-citrate lyase (ACL) inhibitorPrescription requiredEvidence B
⚠ Not medical advice.Not medical advice. This page is educational. Discuss with your physician before starting, changing, or stopping any medication.
Why it matters
For the substantial minority of patients who genuinely cannot tolerate statins, bempedoic acid offered the first major option with proven outcomes data. CLEAR Outcomes (Nissen et al., NEJM 2023) randomized over 13,000 statin-intolerant patients and showed a 13% reduction in major adverse cardiovascular events. The mechanism is elegant: bempedoic acid is a prodrug activated only in the liver (skeletal muscle lacks the activating enzyme ACSVL1), so muscle complaints are no more common than placebo. It inhibits ATP-citrate lyase one step upstream of HMG-CoA reductase, achieving roughly 17-19% LDL-C and 15% ApoB reductions as monotherapy. Combined with ezetimibe (Nexlizet), the reduction approaches 38% - rivaling moderate-intensity statin therapy without muscle risk. Bonus: hsCRP drops about 22%, suggesting genuine anti-inflammatory benefit beyond lipid lowering. The trade-offs are higher cost (no generic), modest hyperuricemia, and a small increase in tendon rupture risk. For ApoB-focused men intolerant to statins, bempedoic acid is now standard.
Uses
Label uses (approved)
- Adjunct to maximally tolerated statin in primary hypercholesterolemia or established ASCVD
- Statin-intolerant adults requiring additional LDL-C lowering
- Heterozygous familial hypercholesterolemia
Off-label (educational only)
- Statin-intolerant patients seeking high-intensity LDL-C reduction — CLEAR Outcomes demonstrated MACE reduction in statin-intolerant population - first non-statin ASCVD primary endpoint win since ezetimibe
- ApoB target stacking with statin plus ezetimibe — Adds ~17% LDL-C reduction beyond statin/ezetimibe
Dosing
Label dose
180 mg orally once daily
Off-label / biohacker dose
180 mg daily (no titration; flat dose-response)
Titration: No titration required. Recheck lipids at 4-12 weeks. Often co-formulated with ezetimibe (Nexlizet) for combined ~38% LDL-C reduction. Check baseline uric acid and gout history before initiation.
When to take: Any time of day, with or without food.
Side effects & warnings
Common
- Upper respiratory infection
- Muscle spasm
- Hyperuricemia
- Back pain
- Abdominal pain
Uncommon but serious
- Gout flare (especially with prior gout)
- Tendon rupture (rare)
- Atrial fibrillation (slight increase in CLEAR Outcomes)
- Elevated creatinine (benign, due to OAT2 inhibition)
Serious warnings
Increased risk of tendon rupture; avoid in patients with tendinopathy history. Hyperuricemia can precipitate gout. Avoid concurrent simvastatin >20 mg or pravastatin >40 mg (increased myopathy risk).
Biomarkers affected
apob
decrease~15% ApoB reduction; ACL inhibition upstream of HMG-CoA reductase
Evidence: strong
hscrp
decrease~22% hsCRP reduction in CLEAR Outcomes; anti-inflammatory beyond lipid effect
Evidence: moderate
ldl c
decrease17-19% LDL-C reduction monotherapy; up to 38% combined with ezetimibe
Evidence: strong
uric acid
variableRaises uric acid via OAT2 inhibition; ~10% develop hyperuricemia, 1-2% gout flare
Evidence: moderate
Monitoring
Lipid panel + ApoB at 4-12 weeks; uric acid at baseline and 4 weeks; assess for tendinopathy symptoms
The honest risk picture
The most clinically important adverse effect is hyperuricemia, occurring in about 10% of patients with a roughly 50% relative increase in gout incidence (1-2% absolute over a year). Check baseline uric acid and personal gout history before starting. A small but real increase in tendon rupture has been reported - patients with a history of tendinopathy or concurrent fluoroquinolone use should avoid the drug. CLEAR Outcomes detected a slight uptick in atrial fibrillation that requires monitoring in patients with prior arrhythmia. Mild elevation in serum creatinine is common and benign, reflecting OAT2 transporter inhibition rather than true renal injury. Importantly, do not combine bempedoic acid with simvastatin doses above 20 mg or pravastatin above 40 mg due to increased myopathy risk through transporter interactions. Gallstone-related events are slightly more frequent, particularly in patients with cholelithiasis history. The drug is contraindicated in pregnancy. Cost remains a barrier in many markets; insurance often requires documented statin intolerance.
Practical context
Cost (US, retail)
$400/mo
Legality
FDA-approved 2020; Rx required. Not yet available as generic.
Interactions
true
FAQ
Does bempedoic acid cause muscle pain?+
No - that is the key feature. Because it requires ACSVL1 to activate, and skeletal muscle does not express this enzyme, bempedoic acid does not cause statin-like myopathy. CLEAR Outcomes confirmed this in a statin-intolerant population.
Will bempedoic acid raise my uric acid?+
Yes, modestly. About 3-5% of patients develop hyperuricemia and roughly 1-2% experience gout flare. Check uric acid before and 4 weeks after starting.
How does it compare to a statin?+
Less potent (about 17-20% LDL-C reduction versus 30-50% for moderate-high intensity statins), but useful for statin-intolerant patients or as an add-on.
The prime report
Weekly performance intelligence.
New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.